Fundamental analysis · SEC EDGAR · TTM through 30/06/2026
EW · NYSE · Healthcare
Fundamental quality
66
out of 100
Edwards Lifesciences Corp runs like a cash machine: it converts about 22% of revenue into free cash flow and holds a 15.4% net margin, though it grows at a measured pace. On fundamental quality it scores 66 out of 100, profiling it as a company of reasonable quality. Its weakest area is its growth (revenue +7.5%/yr). Whether it's cheap or expensive depends on the current price, which you can compute in the tool.
Edwards Lifesciences dominates transcatheter heart valves: devices that replace a heart valve through an artery, without opening the chest. It turned major surgery into a one-day procedure and built formidable leadership on that revolution.
EPS growth: -8.6% · Revenue growth: 7.5%
Net margin: 15.4% · ROE: 9.5% · ROIC: 12%
Net debt/EBITDA: -1.43x · FCF: 22%
Source: SEC EDGAR · TTM through 30/06/2026
The score combines growth, profitability and financial strength. Here its financial strength weighs in its favor, while its growth drags it down the most.
Percentile against the other 57 Healthcare companies in our coverage: how far it beats them on each metric (100 = best in sector).
Computed from the daily dataset scores. A high percentile places the company among the best in its sector on that metric; it is not a buy recommendation.
Key concepts
What do these metrics mean? Fundamental analysis · What is the P/E · What is EPS · What is ROE · Net & gross margin · Free cash flow
| Year | Revenue | Net income | Free cash flow | Net debt |
|---|---|---|---|---|
| 2010 | 1,447 | 218 | 190 | -396 |
| 2021 | 5,233 | 1,503 | 1,406 | -267 |
| 2022 | 4,464 | 1,522 | 974 | -173 |
| 2023 | 5,010 | 1,402 | 643 | -535 |
| 2024 | 5,440 | 4,175 | 290 | -2,447 |
| 2025 | 6,068 | 1,074 | 1,335 | -2,340 |
Between 2010 and 2025, revenue went from $1,447M to $6,068M (+319%) and net income went from $218M to $1,074M (+392%). Meanwhile, its margins have widened (from 15% to 18%).
Annual figures in millions of U.S. dollars ($M) per SEC filings. Net debt is total debt minus cash.
Latest results
Figures for the half-year ended June 30, 2026, versus the half-year ended June 30, 2025 (SEC filings):
Automatic comparison between the two most recent periods filed with the SEC. One quarter doesn't make a trend: read it alongside the historical evolution above.
This company doesn't pay a dividend: it reinvests all its earnings back into the business.
Open your account in minutes with regulated brokers and buy U.S. and European stocks from small amounts. No paperwork.
The serious investor's standard
Open free account →Anyone who wants low commissions and access to almost any market in the world.
Popular in the U.S.
Open free account →Anyone investing in the U.S. who wants a powerful, commission-free stock app.
Investing carries risk of loss.
Is Edwards Lifesciences Corp cheap or expensive?
That depends on the current price. Look it up, enter it in the tool and get the full valuation verdict (P/E against its sector).
Compute the valuation →Is Edwards Lifesciences Corp a good company to invest in?
In terms of business quality, Edwards Lifesciences Corp scores 66 out of 100 in our analysis, placing it as a company of reasonable quality. That said, this isn't a recommendation: whether it's a good investment also depends on its current price and your goals.
Is Edwards Lifesciences Corp a profitable company?
Yes. Edwards Lifesciences Corp shows a net margin of 15.4% and an ROE of 9.5%, a sign of a profitable business.
Does Edwards Lifesciences Corp have a lot of debt?
No. Edwards Lifesciences Corp has a net cash position: more cash than debt.
Is Edwards Lifesciences Corp growing?
Its revenue has grown 7.5% annualized in recent years.
Does Edwards Lifesciences Corp generate cash?
Yes. It converts about 22% of its revenue into free cash flow, and has done so positively year after year.
The thresholds are general and the system doesn't judge qualitative factors. See the full methodology and use this analysis as a first filter, never as a final decision.
More Healthcare companies
3M (MMM) · HCA Healthcare (HCA) · Becton Dickinson (BDX) · GE HealthCare (GEHC) · Idexx Laboratories (IDXX) · Dexcom (DXCM) · see more →
The best Healthcare stocks by our model →
Compare Edwards Lifesciences Corp with 500+ companies in the screener →
Who's behind the methodology and model · how the score is computed
Data: see Edwards Lifesciences Corp's filings on EDGAR
Spotted a figure that looks wrong? Report it and we'll review it.